Index

Brivaracetam

Substansgruppe(r) Antiepileptika
Salgsnavn Briviact
ATC-kode N03AX23
CAS-nummer 357336-20-0
Molekylvekt 212,29
Biotilgjengelighet >90 %
Tmax 1-2 timer
Proteinbinding <20 %
Distribusjonsvolum 0,5-0,6 liter/kg
Blod/plasma-ratio
Halveringstid 6-8 timer
Referanseområde 1 – 10 μmol/L

Pubchem

Sargentini-Maier et al. Drug Metab Dispos 2008;36(1):36-45

Rolan et al. Br J Clin Pharmacol. 2008;66(1): 71–75

Schoemaker R, Wade JR, Stockis A. Brivaracetam population phar­macokinetics and exposure-response modeling in adult subjects with partial-onset seizures. J Clin Pharmacol. 2016;56(12):1591–1602

Hagemann A, Klimpel D, Bien CG, Brandt C, May TW. Influence of dose and antiepileptic comedication on brivaracetam serum concentrations in patients with epilepsy. Epilepsia. 2020 Apr 18. doi: 10.1111/epi.16500


Sist oppdatert 29. april 2020

Tilgjengelige analyser

Plasma/Serum

Analysenavn Metode Laboratorium Mer info
Brivaracetam LC-MS/MS Klinisk farmakologi St Olav (St Olavs hospital) Mer info
Brivaracetam LC-MS/MS Klinisk farmakologi OUS Spesialsykehuset for epilepsi (SSE) (Oslo universitetssykehus) Mer info

Fullblod

Analysenavn Metode Laboratorium Mer info
Brivaracetam LC-MS/MS Klinisk farmakologi St Olav (St Olavs hospital) Mer info